Polomar Health Services, Inc. Annual Report Summary

I’ve put together this guide to help you understand how Polomar Health Services performed this year. My goal is to turn complex financial filings into plain English so you can decide if this company fits your investment goals.

1. What does this company do?

Polomar Health Services is a Florida-based specialty pharmacy. They focus on "compounding," which means creating custom medications—like weight-loss drugs and specialized skin creams—that large manufacturers don't mass-produce. The company is shifting from a local pharmacy model to a national, digital-first business. A key part of this move is "SlimRx," an online platform connecting patients with doctors for weight-loss prescriptions, expected to launch in early 2026.

2. Financial performance

The company is currently operating at a loss. These financial pressures stem from high labor costs during their business transition and falling revenue as they phase out older product lines. They are moving away from local skin-care prescriptions to focus on online sales of weight-loss and erectile dysfunction drugs. Supply chain issues and operational inefficiencies have made it difficult to scale this new business effectively.

3. Major wins and challenges

In September 2024, the company completed a merger to become a pharmacy-focused business. To compete with telehealth giants, Polomar plans to offer weight-loss drugs in "pre-filled injection pens," which management believes will be more user-friendly than the traditional vials and syringes used by competitors. However, the company faces a cash crisis. They currently lack the funds to cover daily operations and are relying on loans from individuals with close ties to the company to stay afloat.

4. Financial health

The company is in "survival mode." Management has stated they lack the cash needed to carry out their business plan. To raise money, they expect to issue more shares, which will reduce your ownership percentage in the company. Additionally, they reported "material weaknesses" in their internal controls. This means their accounting and record-keeping systems are not currently reliable enough to guarantee accurate financial statements, which represents a significant risk for investors.

5. Key risks

• Survival: The company has a history of losses and cannot guarantee it will become profitable or remain in business.
• Dilution: Issuing more shares to raise cash will likely decrease the value and percentage of your ownership.
• Stock Market Status: This is a "penny stock." It is highly volatile, hard to trade, and not listed on major exchanges, making it difficult to buy or sell.
• Legal/Regulatory: The business relies on specific licenses and patents. If they lose their pharmacy licenses or face successful patent lawsuits, the company would have to shut down immediately.

6. Future outlook

The company’s future depends on a "wholesale" model where they partner with third-party online platforms to ship prescriptions. Growth is tied to their ability to secure pharmacy licenses in every state by mid-2026. Ultimately, the company is in a high-stakes race to grow its customer base before it runs out of cash.

A final thought for your decision-making: When looking at a company in "survival mode," it is helpful to weigh the potential of their new digital platform against the significant risks of dilution and unreliable internal accounting. Given the company's current reliance on emergency loans and the volatility of penny stocks, this investment carries a high level of uncertainty. Always consider whether this fits your personal risk tolerance before moving forward.